How many drugs treat Tonic-clonic seizure?

Drug Landscape tracks 7 marketed treatments for Tonic-clonic seizure (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tonic-clonic-seizure.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Tonic-clonic seizure — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tonic-clonic seizure (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tonic-clonic seizure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tegretol	carbamazepine	Novartis AG (originally Geigy)	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
Mysoline	PRIMIDONE	Bausch Health	Anti-epileptic Agent [EPC]	Transient receptor potential cation channel subfamily M member 3	1954-01-01
Dilantin	Phenytoin Sodium	Pfizer	phenytoin	Nuclear receptor subfamily 1 group I member 3	1953-01-01
Phenytoin Sodium	PHENYTOIN	Viatris	Anti-epileptic Agent	Sodium channel protein type 2 subunit alpha	1953-01-01
Carbamazepin	Carbamazepin	Enanta Pharmaceuticals, Inc		Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4
Lamictal	lamotrigine	GSK	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha
phenobarbitone	phenobarbitone	Institute of Child Health		Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bausch Health · 1 drug in Tonic-clonic seizure
Enanta Pharmaceuticals, Inc · 1 drug in Tonic-clonic seizure
GSK · 1 drug in Tonic-clonic seizure
Institute of Child Health · 1 drug in Tonic-clonic seizure
Novartis AG (originally Geigy) · 1 drug in Tonic-clonic seizure
Pfizer · 1 drug in Tonic-clonic seizure
Viatris · 1 drug in Tonic-clonic seizure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tonic-clonic seizure:

Cite this brief

Drug Landscape (2026). Tonic-clonic seizure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tonic-clonic-seizure. Accessed 2026-06-11.

Tonic-clonic seizure full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing